The 2016 WHO classification revised the myelodysplastic syndrome (MDS)-related cytogenetic abnormalities: del (9q) was removed and patients with mutated NPM1 or biallelic CEBPA were recategorized as having recurrent genetic abnormalities [2]. This evidence concerns the gene NPM1 and myelodysplastic syndrome.